Sinopharm Group Co. Ltd. (HKG:1099)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 63.79B +11.3% |
| Revenue (ttm) | 640.05B -1.6% |
| Net Income | 7.96B +1.5% |
| EPS | 2.55 +1.5% |
| Shares Out | 3.12B |
| PE Ratio | 8.01 |
| Forward PE | 7.13 |
| Dividend | 0.79 (3.90%) |
| Ex-Dividend Date | Jun 23, 2026 |
| Volume | 1,829,962 |
| Average Volume | 4,978,847 |
| Open | 20.66 |
| Previous Close | 20.32 |
| Day's Range | 20.34 - 20.66 |
| 52-Week Range | 17.28 - 22.34 |
| Beta | 0.60 |
| RSI | 45.71 |
| Earnings Date | Apr 24, 2026 |
About Sinopharm Group
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added... [Read more]
Financial Performance
In 2025, Sinopharm Group's revenue was 575.17 billion, a decrease of -1.60% compared to the previous year's 584.51 billion. Earnings were 7.16 billion, an increase of 1.50%.
Financial numbers in CNY Financial StatementsNews
OSRH Subsidiary Woori IO Partners with Sinopharm Group in Strategic NDA
OSRH Subsidiary Woori IO Partners with Sinopharm Group in Strategic NDA
Here Are All the COVID-19 Vaccines Currently in Clinical Testing
Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.